- Home
- LSF vs INAB Comparison
LSF vs INAB Comparison
Compare LSF & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | INAB |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 22.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSF | INAB |
|---|---|---|
| Price | $2.69 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $180.00 |
| AVG Volume (30 Days) | ★ 66.9K | 36.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 43.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $0.12 |
| 52 Week High | $7.94 | $4.20 |
Technical Indicators
Market Signals| Indicator | LSF | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 43.62 |
| Support Level | $2.46 | $1.52 |
| Resistance Level | $2.76 | $2.55 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 34.68 | 42.11 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.